Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Application of Pirfenidone as a Radiosensitizer in the Treatment of Head and Neck Squamous Cell Carcinoma: Phase II Clinical Study

NCT06142318 is registered in ClinicalTrials.gov with Nanfang Hospital, Southern Medical University as lead sponsor.

NCT NCT06142318
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06142318 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Application of Pirfenidone as a Radiosensitizer in the Treatment of Head and Neck Squamous Cell Carcinoma: Phase II Clinical Study
Lead sponsor
Nanfang Hospital, Southern Medical University
Phase
Phase 2
Overall status
Unknown status
Start date
November 15, 2023
Completion date
June 30, 2025
Enrollment
66 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

head and neck squamous cell carcinoma, pirfenidone, radiosensitizer, radiotherapy